Richard J. Berman
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioVie Featured on Bloomberg Television Segment. BioVie was included in a new episode of The Street Show airing on Bloomberg Television. The segment also featured Glint, Sagtec Global, and SafeSpace Global. This media appearance provides additional visibility for the company to a financial audience.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
BTIG Keeps CryoPort Target at $25 Amid Cell Therapy Pipeline. BTIG reiterated its positive stance on CryoPort, maintaining a $25 price target. This follows commentary highlighting the company's strong pipeline of cell and gene therapy approvals. The stock is currently trading near the upper end of its 52-week range, reflecting recent momentum in the sector.
Transaction History
| CELU | ▲ Buy | Grant | 67,416 | $0 | 12/19/2024 | View on chart |
| BIVI | ▲ Buy | Grant | 34,200 | $0 | 11/20/2024 | View on chart |
| CYRX | ▲ Buy | Grant | 12,845 | $0 | 5/17/2024 | View on chart |
| CYRX | ▼ Sell | Open Market | 8,105 | $109K | 5/15/2024 | View on chart |
| BIVI | ▲ Buy | Grant | 51,830 | $0 | 11/9/2023 | View on chart |
| BIVI | ▼ Sell | Open Market | 10,805 | $38K | 8/22/2023 | View on chart |
| BIVI | ▼ Sell | Open Market | 5,984 | $35K | 6/7/2023 | View on chart |
| BIVI | ▼ Sell | Open Market | 5,000 | $33K | 5/22/2023 | View on chart |
| CYRX | ▲ Buy | Grant | 8,105 | $0 | 5/12/2023 | View on chart |
| CYRX | ▼ Sell | Open Market | 7,203 | $155K | 5/11/2023 | View on chart |
| BIVI | ▼ Sell | Open Market | 5,000 | $43K | 3/28/2023 | View on chart |
| BIVI | ▼ Sell | Open Market | 2,613 | $22K | 3/28/2023 | View on chart |
| BIVI | ▼ Sell | Open Market | 3,371 | $29K | 3/27/2023 | View on chart |
| CYRX | ▼ Sell | Open Market | 7,250 | $142K | 12/1/2022 | View on chart |
| BIVI | ▲ Buy | Grant | 43,578 | $0 | 11/23/2022 | View on chart |
| CYRX | ▼ Sell | Open Market | 2,708 | $117K | 8/16/2022 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 2,708 | — | 4/30/2022 | View on chart |
| CYRX | ▲ Buy | Grant | 7,203 | $0 | 4/29/2022 | View on chart |
| CYRX | ▼ Sell | Open Market | 3,703 | $232K | 9/15/2021 | View on chart |
| CYRX | ▼ Sell | Open Market | 15,073 | $966K | 9/15/2021 | View on chart |
| CYRX | ▼ Sell | Open Market | 6,224 | $402K | 9/15/2021 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 14,134 | $203K | 9/13/2021 | View on chart |
| CYRX | ▲ Buy | Option Exercise | 10,866 | $196K | 9/13/2021 | View on chart |
| BIVI | ▲ Buy | Grant | 1,600 | $0 | 1/2/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Celularity Q1 2027 EPS Up, Announces Partner & Board Member
Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.
Celularity Q1 2027 EPS Up, Announces Partner & Board Member. Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.